Prof. İBRAHİM HALİL GÜLLÜ

Personal Information

Email: ibrahimhalil.gullu@hacettepe.edu.tr
Web: https://avesis.hacettepe.edu.tr/ibrahimhalil.gullu

Published journal articles indexed by SCI, SSCI, and AHCI

I. **Post-induction lymph node delineation in nasopharyngeal cancer: A single-center experience.**
Sari S., YİĞİT E., YAZICI G., GÜLLÜ İ. H., AKSOY S., ÖZYİĞİT G., CENGİZ M.
Head & neck, vol.45, no.3, pp.612-619, 2023 (SCI-Expanded)

II. **Cancer incidence in Behcet's Disease.**
Guven D. C., Bolek E. C., Altintop S. E., Celikten B., Aktas B. Y., Kiraz S., Gullu I. H., Karadag O., Dizdar O.
JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15, 2020 (SCI-Expanded)

III. **Neoadjuvant Chemotherapy Improves Survival in Patients with Locally Advanced Nasopharyngeal Carcinoma**
Basaran H., CENGİZ M., YAZICI G., Susulu N., AKSOY S., HOŞAL A. Ş., GÜLLÜ İ. H., ÖZYİĞİT G.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, vol.29, no.3, pp.176-185, 2019 (SCI-Expanded)

IV. **Detection of O6-methylguanine-DNA methyltransferase gene promoter region methylation pattern using pyrosequencing and the effect of methylation pattern on survival, recurrence, and chemotherapy sensitivity in patients with laryngeal cancer**
Celebi O. O., Tezel G. G., Hosal A. S., CENGİZ M., GÜLLÜ İ. H., HAYRAN K. M.
PATHOLOGY RESEARCH AND PRACTICE, vol.212, no.5, pp.456-462, 2016 (SCI-Expanded)

V. **Successful treatment of benign metastasizing leiomyoma with oral alternated chemotherapeutic agents**
Sarici F., Babacan T., Altundag K., Balakan O., Gullu I.
JOURNAL OF BUON, vol.18, no.3, pp.799, 2013 (SCI-Expanded)

VI. **Long-term advanced cholangiocarcinoma survivor with single-agent capecitabine**
Petekkaya I., Gezgen G., Roach E. C., Solak M., Altundag K., Gullu I.
JOURNAL OF BUON, vol.17, no.4, pp.796, 2012 (SCI-Expanded)

VII. **SALVAGE REIRRADIATON WITH STEREOTACTIC BODY RADIOTHERAPY FOR LOCALLY RECURRENT HEAD-AND-NECK TUMORS**
CENGİZ M., ÖZYİĞİT G., YAZICI G., DOĞAN A., YILDIZ F., Zorlu F., Gurkaynak M., GÜLLÜ İ. H., Hosai S., Akyol F.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol.81, no.1, pp.104-109, 2011 (SCI-Expanded)

VIII. **Clinicopathologic evaluation of non-Hodgkin lymphoma (NHL): A single centre experience**
Kilickap S., Barista I., Turkmen E., Dizdar O., Aksoy S., Turker A., Gullu I., Ozisik Y., Kars A., Tekuzman G.
JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (SCI-Expanded)

IX. **Potential molecular targeted therapies in the management of the basal-like subtype of breast cancer**
KURT M., Harputluoglu H., ŞENER DEDE D., GÜLLÜ İ. H., Altundag K.
BREAST, vol.16, no.2, pp.111-112, 2007 (SCI-Expanded)

X. **Mucosa associated lymphoid tissue lymphoma of the sub mandibular gland presenting with relapse in the lacrimal gland**
KURT M., Shorbagi A., ALTUNDAĞ M. K., AKYÖN YILMAZ Y., DİZDAR Ö., GÜLLÜ İ. H.
Leukemia, vol.47, pp.1982-1984, 2006 (SCI-Expanded)

XI. **Complications due to late diagnosis of celiac disease with co-existing plasma cell dyscrasia in an**

elderly patient
Cankurtaran M., Ulger Z., Dogan S., Yavuz B., Halil M., Gullu I., Gedikoglu G., Ariogul S.
AGING CLINICAL AND EXPERIMENTAL RESEARCH, vol.18, no.1, pp.75-77, 2006 (SCI-Expanded)

XII. **Peripheral T-cell lymphoma and Job's syndrome**
Onal I., Kurt M., Altundag K., Aksoy S., Dincer M., Gullu I.
MEDICAL ONCOLOGY, vol.23, no.1, pp.141-144, 2006 (SCI-Expanded)

XIII. **Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia**
Kurt M., Shorbagi A., Altundag K., Elkiran T., Gullu I., Kansu E.
AMERICAN JOURNAL OF HEMATOLOGY, vol.80, no.3, pp.213-215, 2005 (SCI-Expanded)

XIV. **Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: Results of single-center study of 45 patients**
Altundag O., Gullu I., Altundag K., Yalcin S., Ozyar E., Cengiz M., Akyol F., Yucel T., Hosal S., Sozeri B.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, vol.27, no.1, pp.15-21, 2005 (SCI-Expanded)

XV. **Acute tumor lysis syndrome triggered by zoledronic acid in a patient with metastatic lung adenocarcinoma**
Kurt M., Onal I., Elkiran T., Altun B., Altundag K., Gullu I.
MEDICAL ONCOLOGY, vol.22, no.2, pp.203-206, 2005 (SCI-Expanded)

XVI. **Calcium and vitamin D supplementation during bisphosphonate administration may increase osteoclastic activity in patients with bone metastasis**
Altundag O., Altundag K., Silay Y., Gunduz M., Demircan K., Gullu I.
MEDICAL HYPOTHESES, vol.63, no.6, pp.1010-1013, 2004 (SCI-Expanded)

XVII. **Hypocalcemic effect of zoledronic acid or other bisphosphonates may contribute to their antiangiogenic properties**
Aksoy S., Abali H., Dincer M., Kilickap S., Gullu I., Tekuzman G.
MEDICAL HYPOTHESES, vol.62, no.6, pp.942-944, 2004 (SCI-Expanded)

XVIII. **Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with cisplatin-based chemotherapy**
Altundag K., Aksoy S., Gullu I., Altundag O., Ozyar E., Yalcin S., Cengiz M., Akyol F.
MEDICAL ONCOLOGY, vol.21, no.3, pp.211-215, 2004 (SCI-Expanded)

XIX. **Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer**
Yalcin S., Oksuzoglu B., Tekuzman G., Engin H., Celik I., Turker A., Barista I., Gullu I., Guler N., Altundag K., et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.33, no.11, pp.580-583, 2003 (SCI-Expanded)

XX. **Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based chemotherapy: Efficacy and prognostic factors**
Karaoglu A., Yalcin S., Tekuzman G., Kars A., Celik I., Guler N., Ozisik Y., Turker A., Barista I., Gullu I.
TUMORI, vol.89, no.2, pp.141-145, 2003 (SCI-Expanded)

XXI. **Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy**
Barista I., Tekuzman G., Yalcin S., Gullu I., Guler N., Ozisik Y., Kars A., Celik I., Turker A., Altundag K., et al.
JOURNAL OF SURGICAL ONCOLOGY, vol.73, no.1, pp.12-16, 2000 (SCI-Expanded)

XXII. **Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections**
Akova M., Ozcebe O. İ., Gullu I., Unal S., GUR D., AKALIN S., TOKGOZOGLU M., TELATAR F., AKALIN H.
JOURNAL OF CHEMOTHERAPY, vol.8, no.4, pp.284-289, 1996 (SCI-Expanded)

Articles Published in Other Journals

I. **Outcome of Elderly Nasopharyngeal Carcinoma Patients: A Single Center Study**
Basaran H., CENGİZ M., YAZICI G., Ozdemir Y., SÜTAY SÜSLÜ N., GÜLLÜ İ. H., ÖZYİĞİT G.
EUROPEAN JOURNAL OF THERAPEUTICS, vol.26, no.2, pp.129-134, 2020 (ESCI)

II. **The Synergistic Effect of Immune Checkpoint Blockade and Radiotherapy in Recurrent/Metastatic Sinonasal Cancer**
YAZICI G., GÜLLÜ İ. H., CENGİZ M., ELMALI DOĞAN A., YILMAZ M. T., AKSOY S., YÜCE SARI S., ÖZYİĞİT G.
Cureus, vol.10, pp.3519, 2018 (ESCI)

III. **How would you manage a rare cause of haemoptysis?**
Ulubay G., Gorek A., Akcay S., Gullu I.
BREATHE, vol.3, no.2, pp.203-205, 2006 (ESCI)

IV. **Metastatic biology**
GÜLLÜ İ. H., Akalin I.
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, vol.4, no.4, pp.16-19, 2005 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

I. **Baş-Boyun Melanomlarında Radyoterapi Sonuçlarımız**
YÜCE SARI S., YAZICI G., CENGİZ M., YILMAZ M. T., AKSOY S., GÜLLÜ İ. H., ÖZYİĞİT G.
13. ULUSAL RADYASYON ONKOLOJİSİ KONGRESİ, Turkey, 27 April - 01 May 2018

II. **Adjuvan Yoğunluk Ayarlı Radyoterapi Uygulanan Baş-Boyun Kanserli Olgularda Tedavi Sonuçlarımız.**
YÜCE SARI S., CENGİZ M., YAZICI G., ELMALI DOĞAN A., BEDÜK Ç. S., GÜLLÜ İ. H., AKSOY S., ÖZYİĞİT G.
13.Ulusal Radyasyon Onkolojisi Kongresi, Turkey, 27 April - 01 May 2018

III. **Definitif Radyoterapi Uygulanan Lokal İleri Evre Larinks Kanserli Hastalarda Hematolojik Parametrelerin Sağkalım Üzerine Prognostik Etkisi**
YÜCE SARI S., CENGİZ M., GÜLTEKİN M., SÜSLÜ N., YAZICI G., HAYRAN K. M., GÜLLÜ İ. H., ÖZYİĞİT G.
22. UKK, Turkey, 19 - 23 April 2017

IV. **Survival and Larynx Preservation Rates after Definitive Radiotherapy A Single Center Experience**
CENGİZ M., YÜCE SARI S., GÜLTEKİN M., SÜSLÜ N., AKSOY S., KUŞCU O., ÖZYİĞİT G., HOŞAL Ş., HAYRAN K. M., GÜLLÜ İ. H.
ECHNO 2016, Budapest, Hungary, 7 - 10 September 2016

V. **The impact of the total size of lesions in multifocal multicentric breast cancer on survival**
Karakaş Y., DİZDAR Ö., Akın S., ATEŞ Ö., ŞENDUR M. A. N., AKSOY S., GÜLLÜ İ. H., ÖZIŞIK Y. Y., ALTUNDAĞ M. K.
2016 ASCO Annual Meeting, 29 May - 03 June 2016

VI. **Modified docetaxel cisplatin and fluorouracil therapy as a first line treatment for patients with recurrent metastatic squamous cell carcinoma of the head and neck cancer a retrospective study**
DEMİRCİ N., AKSOY S., ÖZDEMİR N., Babacan T., ERDEM G. U., BOZKAYA Y., ZENGİN N., GÜLLÜ İ. H.
2016 ASCO Annual Meeting, 29 May - 03 June 2016

VII. **Radiation Therapy Results of Patients With Adenoid Cystic Carcinoma**
GÜLTEKİN M., CENGİZ M., Sari S. Y., HOŞAL Ş., YAZICI G., SÜSLÜ N., Can O. B., GÜLLÜ İ. H., ÖZYİĞİT G.
57th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), San-Antonio, Northern Mariana Islands, 18 - 21 October 2015, vol.93

VIII. **Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC versus DCF.**
Kertmen N., Aksoy S., Cengiz M., Yazici G., Keskin O., Babacan T., Sarici S. F., Akin S., Altundag K., Gullu I. H.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

IX. **Outcomes of patients with HER2-negative breast cancer with central nervous system metastasis treated with capecitabine.**
Altundag K., Aksoy S., Sendur M. A. N., Guler E. N., Gullu I. H., Ozisik Y. Y.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

X. **Early stage "T2N0" breast cancer: Does it consist two different "T2" stages?**
Arslan C., Sahin U., Kizilarslanoglu C., Solak M., Gullu I. H., Ozisik Y., Altundag K.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

XI. **Comparison of ER, PR, HER2 in primary and paired relapsed/metastatic lesions of metastatic breast cancer patients**
SARI E., Guler G., HAYRAN K. M., Altundag K., GÜLLÜ İ. H., Ozisik Y.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27

XII. **Comparison of serum levels of CEA and CA 15-3 in triple-negative breast cancer at the time of metastases and serum levels at the time of first diagnosis**
Dede D. S., Aksoy S., Bulut N., Dizdar O., Arik Z., Gullu I., Ozisik Y., Altundag K.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27

XIII. **Characteristics of breast cancer patients with central nervous system metastases and factors associated with survival after development of central nervous system metastasis**
Harputluoglu H., Dizdar O., Aksoy S., Kilickap S., Dede D. S., Ozisik Y., Guler N., Barista I., Gullu I., Selek U., et al.
30th Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 13 - 16 December 2007, vol.106

XIV. **Serum LDH level is a prognostic factor in locoregionally advanced nasopharyngeal carcinoma (NPC) patients treated with chemoradiotherapy**
Turen S., Ozyar E., Altundag K., Gullu I., Atahan I.
23rd Annual Meeting of the European-Society-for-Therapeutic-Radiology-and-Oncology (ESTRO 23), Amsterdam, Netherlands, 24 - 28 October 2004, vol.73

XV. **Clinicopathological features and outcome of primary gastric lymphoma: A series of 73 cases**
Oyan B., Tekuzman G., Barista I., Kars A., Turker A., Ozisik Y., Guler N., Baltali E., Yalcin S., Gullu I.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

Metrics

Publication: 44
Citation (WoS): 208
Citation (Scopus): 117
H-Index (WoS): 8
H-Index (Scopus): 3